N-piperidine Ibrutinib is a key synthetic intermediate used in the production of Ibrutinib, a targeted therapy for B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. This compound features a piperidine ring attached to the core pyrazolo[3,4-d]pyrimidine scaffold of Ibrutinib. In the final synthesis step, the piperidine nitrogen is acylated with an acryloyl group to form the active BTK inhibitor. As an intermediate, it plays a crucial role in enabling the selective inhibition of Bruton's tyrosine kinase (BTK) in the complete drug molecule, supporting the treatment of hematologic cancers.